Global Neurological Biomarkers Market Set for Significant Growth, Projected to Reach USD 12.5 Billion by 2033 with a steady CAGR of 4.6%

The global neurological biomarkers market is poised for remarkable growth, driven by the increasing demand for accurate diagnosis and treatment monitoring of neurological disorders. According to a recent market analysis, the sector is projected to witness a robust Compound Annual Growth Rate (CAGR) of 4.6% over the forecast period, reaching an estimated USD 12.5 billion by 2033. In 2023, the market was valued at USD 8 billion, highlighting a notable upward trajectory.

Neurological biomarkers play a critical role in the diagnosis and monitoring of various neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. These advancements in precision medicine are propelling the growth of the neurological biomarkers market. The increasing demand for enhanced diagnostic tools and effective treatment monitoring solutions is further fueling the sector’s expansion.

Request A Sample Copy:

As the prevalence of neurological disorders continues to rise globally, the need for innovative and precise diagnostic methods becomes increasingly imperative. Neurological biomarkers offer the promise of early detection and more personalized treatment plans, significantly improving patient outcomes.

The market growth is also being driven by substantial investments in research and development, as well as collaborations between pharmaceutical companies and research institutions. These efforts are aimed at discovering new biomarkers and developing advanced diagnostic technologies.

The forecasted growth of the neurological biomarkers market underscores the importance of continued innovation and investment in this vital field. With the increasing burden of neurological diseases on healthcare systems worldwide, the expansion of this market is crucial in addressing unmet medical needs and improving the quality of life for millions of patients.

Key Takeaways:

  • During the forecast period, the US is expected to account for a significant share of the global neurological biomarkers market. This is attributed to the best scientists and industry-leading laboratories who drive the development of more advanced biomarker tactics, as well as specialized testing and on-target protocol help, to accelerate clinical biomarkers projects.
  • The neurological biomarkers market in the Asia-Pacific is predicted to hold the largest share, particularly in Japan and India, during the projected period. This is owing to the launch of novel solutions such as PET scanners with motion correction, as well as the development of methods that enable significantly earlier sickness diagnosis, improved prognoses, and increased treatment options in order to increase the lifetime of future generations.
  • Owing to expanding research and development initiatives towards the production of personalized medications for neurological illnesses, the “genomic biomarkers” type is expected to hold the highest revenue through the forecast period.
  • As it is the most common of all neurological disorders, the “Alzheimer’s disease” application type accounts for a significant share and is the most profitable area for manufacturers.

Visit for Customization:

Competitive Landscape:

Industry players engage in numerous planned product launches and global expansion to promote the brand and sales. They are also expanding their presence across various geographies and entering new markets, especially in developing regions, to expand their customer base and strengthen their presence. The introduction of new innovative products in the market is also being carried out by market players, owing to the increasing number of neurological disorders across the world. These factors are anticipated to expand the global neurological biomarkers market size. The following companies are key leaders in the global market for neurological biomarkers:

  • Quanterix
  • Qiagen
  • ADx NeuroSciences NV
  • Merck KGaA
  • Enrolmmun
  • Thermo Fisher Scientific
  • Banyan Biomarkers Inc.
  • Olink Biosciences
  • Bio-Rad Laboratories Inc.

Recent Developments:

  • In August 2020, Johnson & Johnson Services, Inc. entered into an agreement with Enigma Biomedical Group for the evaluation of novel neuroimaging biomarkers-JNJ-64413739 and JNJ-64511070-to understand Alzheimer’s disease and other dementias.
  • In 2019, MC10 Inc. announced the collaboration with the University of Rochester for the development of novel digital biomarkers for central nervous system diseases.

A Detailed Full Report:

Key Segments Profiled in the Neurological Biomarkers Market Survey:

By Type:

  • Genomics Biomarkers
  • Proteomics Biomarkers
  • Metabolomics Biomarkers
  • Imaging Biomarkers
  • Others

By Application:

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Huntington’s Disease
  • Schizophrenia
  • Depression
  • Multiple Sclerosis
  • Spinal Muscular Atrophy

By End User:

  • Research Organizations
  • Pharma & Biotech Companies
  • Clinical Diagnostics

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Middle East and Africa (MEA)
  • Europe

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
LinkedInTwitterBlogs | YouTube

Leave a comment

Your email address will not be published. Required fields are marked *